Menu

Ebola Update

Health officials confirm a case of Ebola in Liberia, which was declared free of transmissions in September. 

Nov 20, 2015
Tracy Vence

CDCWith the country’s first confirmed case since September, Liberia is no longer free of Ebola transmissions, health officials reported today (November 20), according to the Associated Press (AP). A 10-year-old boy who tested positive for the virus is now being treated outside Monrovia, the AP reported. World Health Organization (WHO) spokesperson Tarik Jasarevic confirmed the case in an interview with the Agence France-Presse.

Meanwhile, in its latest report, the WHO noted that there have been no new confirmed cases of Ebola in Guinea since October 29. But there is no official declaration yet of Guinea being rid of the virus. As The New York Times reported this week (November 17), “Guinea and other countries also run the risk of new cases generated from survivors who still harbor the virus in semen or body tissues.”

November 2018

Intelligent Science

Wrapping our heads around human smarts

Marketplace

Sponsored Product Updates

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

Every minute counts when waiting for accurate diagnostic test results to guide critical care decisions, making today's clinical lab more important than ever. In fact, nearly 70 percent of critical care decisions are driven by a diagnostic test.

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC’s Genomics division announced it is transforming its branding under LGC, Biosearch Technologies, a unified portfolio brand integrating optimised genomic analysis technologies and tools to accelerate scientific outcomes.

DefiniGEN licenses CRISPR-Cas9 gene editing technology from Broad Institute to develop cell models for optimized metabolic disease drug development

DefiniGEN licenses CRISPR-Cas9 gene editing technology from Broad Institute to develop cell models for optimized metabolic disease drug development

DefiniGEN Ltd are pleased to announce the commercial licensing of CRISPR-Cas9 gene-editing technology from Broad Institute of MIT and Harvard in the USA, to develop human cell disease models to support preclinical metabolic disease therapeutic programmes.